

# Supplementary Information: $\alpha$ -Synuclein driven cell susceptibility in Parkinson's disease

**Authors:** Jonathan C. Breiter <sup>1,2,3</sup>, <sup>†</sup>, Joseph S. Beckwith <sup>1,3</sup>, <sup>†</sup>, Emma E. Brock <sup>1,3</sup>, Joanne Lachica <sup>3,4,5</sup>, Christina E. Toomey <sup>3,4,6</sup>, Bin Fu <sup>1,3</sup>, Mina Ryten <sup>3,7,8,9</sup>, Lucien E. Weiss <sup>10</sup>, Nicholas W. Wood <sup>3,11</sup>, Sonia Gandhi <sup>3,5,11</sup>, Michele Vendruscolo <sup>1,2,3\*</sup>, Steven F. Lee <sup>1,3\*</sup>

## Affiliations:

<sup>1</sup>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK

<sup>2</sup>Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK

<sup>3</sup>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA

<sup>4</sup>The Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London WC1N 3BG, U.K.

<sup>5</sup>The Francis Crick Institute, 1 Midland Road, London, UK

<sup>6</sup>Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG U.K.

<sup>7</sup>UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, U.K.

<sup>8</sup>Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, U.K.


<sup>9</sup>Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK.

<sup>10</sup>Department of Engineering Physics, Polytechnique Montréal, Montréal, Québec H3T 1J4, Canada

<sup>11</sup>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, U.K.


<sup>†</sup>Contributed equally to this work

\*Corresponding Authors: [sl591@cam.ac.uk](mailto:sl591@cam.ac.uk), [mv245@cam.ac.uk](mailto:mv245@cam.ac.uk)




**Figure S1. There is no difference in aggregate intensity between PD and HC.** Intensity distributions of diffraction-limited  $\alpha$ Syn aggregates detected in  $n = 13$  HCs and  $n = 14$  PD patients in **A.** frontal cortex **B.** temporal cortex **C.** parietal cortex **D.** parahippocampal cortex and **E.** caudate across two repeat imaging runs for each region each disease state. N-numbers represent the total number of aggregates detected across both repeats per region.

38 The dotted horizontal line in violins represents the median, with the upper and lower lines as  
39 the interquartile range (IQR).




40


41 **Figure S2. Anti-pS129 antibody is most suitable for ASA-PD. A.** Simulated microscopy  
42 image-representation highlighting the two data quality requirements for ASA-PD and RASP.<sup>1,2</sup>  
43 Firstly, signal needs to be clearly separated from background intensity with a high  
44 signal/background ratio to detect individual diffraction-limited puncta. Secondly, signal needs  
45 to be sparse enough for spatial separation between point spread functions for accurate  
46 resolution of the location and quantity of puncta. **B.** Four  $\alpha$ Syn antibodies tested in PD Braak  
47 3/4 (n = 1) and HC (n = 1) brain. Signal over background ratio of oligomeric protein assemblies  
48 as detected by antibodies 34-45 (AB\_2650701), 80-96 (AB\_2650688), 5G4 (AB\_2716647)  
49 and pS129 (AB\_2270761). Vertical lines represent the median of each distribution. N-numbers  
50 represent the total number of aggregates detected by the antibody. **C.** Mean  $\pm$  standard  
51 deviation density of aggregates produced by the four antibodies in the human brain. The  
52 pS129 antibody shows the highest signal/background ratio and the lowest density of  
53 diffraction-limited  $\alpha$ Syn aggregates. Low background and high spatial separation of local  
54 maxima is essential for successful small aggregate detection.<sup>1</sup> Additional quantitative  
55 information on the requirements for the antibody election can be found in our previous work.<sup>2</sup>




58 **Figure S3. Brain region aggregate density does not vary between PD and HC.** Per patient  
 59 average density of  $\alpha$ Syn oligomers per  $10 \mu\text{m}^2$  in the frontal cortex (A.), parahippocampal  
 60 cortex (B.) and caudate (C.). Horizontal lines represent the mean  $\pm$  SD across patient means.  
 61 No significant difference is observed between individuals within the HC or PD group per region  
 62 or between the HC and PD group averages in each region.




65 **Figure S4. Evidence for ASCs in microglia. A.** Probability density distributions of the  
 66 aggregate concentration per microglia across three brain regions. **B.** The summary plot shows  
 67 the Mean  $\pm$  SD ratio of PD/HC aggregate concentration as the protein assembly ratio inside  
 68 microglia. **C.** The sub-population of Aggregation Susceptible Cells (ASCs) of microglia as a  
 69 function of a changing threshold on aggregate concentration, where increasing threshold  
 70 corresponds to more extreme values within the aggregate concentration distribution (See  
 71 **Figure 2 C**). **D.** The summary plot shows the Mean  $\pm$  SD ratio PD/HC of ASCs of microglia as  
 72 the cell susceptibility ratio.  
 73  
 74




75 **Figure S5. Statistical determination of minimal critical sample size.** Hellinger Distance  
 76 (HD) between PD and HC distributions in Figure 3 (B.) as a function of subsampled cells  
 77 according to parametric HD<sup>3,4</sup> in frontal cortex (A.), parahippocampal cortex (B.) and caudate  
 78 (C.). The minimum number of cells required to observe the true Hellinger distance between  
 79 HC and PD is determined by subsampling the cell aggregate concentration distributions at  
 80 decreasing n-numbers with 5,000 iterations per step and determining the initial intersection of  
 81 mean  $\pm$  SD across iterations of a subsampling step with the true observed HD. This shows  
 82 the minimum number of neurons that need to be observed and quantified across PD and HC  
 83 groups to power the observations made in **Figure 3 B**. Some points on true HD line are omitted  
 84 for clarity to guide the eye.  
 85




**Figure S6. There is no difference in ASC abundance in unaffected brain regions.** The percentage of Aggregation Susceptible Cells (ASCs) plotted against the scanning threshold set on the joint distribution of  $\alpha$ Syn concentration per cell in the frontal (A.), temporal (B.) and parietal (C.) cortices in PD and HC samples. All three regions are considered to be unaffected by PD pathology in Braak stage 3/4.<sup>5,6</sup>



**Figure S7. Intensity and cellular density of aggregates show no correlation.** Correlation between the local density of diffraction-limited  $\alpha$ Syn aggregates and the intensity per aggregate in PD and HC frontal cortex (A.), parahippocampal cortex (B.) and caudate (C.). The number of aggregates per bin is shown by the lookup colour bar next to each graph.



99  
100 **Figure S8. Cell susceptibility is not dependent on aggregate brightness.** Cell  
101 susceptibility ratio (PD/HC) as a function of the intensity fraction of all observed intracellular  
102  $\alpha$ Syn aggregates in **A.** frontal cortex **B.** parietal cortex **C.** temporal cortex **D.** parahippocampal  
103 cortex and **E.** caudate. Lookup table indicates the number of cells per point on each graph.  
104 Multiple points at each value on the x-axis are based on a scanning threshold (See **Section**  
105 **S4**) from  $T = 0$  to  $T = 3$  in 0.05 steps. The y-axis represents the cell susceptibility ratio (See  
106 **Figure 3 B**) as the ratio of the fraction of ASCs in PD/ ASCs in HC. Red lines represent simple  
107 linear fits weighted by number of cells.



**Figure S9. Cell segmentation is defined by size parameters.** Comparison of un-processed cell mask (left) with processed cell mask (right). Independent unconnected objects of  $\geq 150$  and  $\leq 700 \mu\text{m}^3$  are kept post processing, corresponding to assumed spherical diameters of 6.59–11.02  $\mu\text{m}$ .

113  
114

### **Section S1. Estimation of Lewy Body abundance in Cortical Brain regions**

115 No conclusive quantification of the relative number of Lewy Bodies (LBs) in relation to  
116 the number of neurons in neocortical brain regions such as the frontal cortex exists.  
117 Few studies look at the fraction of neurons containing LBs, with evidence from the  
118 *substantia nigra* showing an average of 3.7% of neurons containing a LB.<sup>7</sup> Across 45  
119 cases, Mattila *et. al.*<sup>8</sup> counted LBs in neocortical regions. On average, they observed  
120 9.22 LBs in the frontal gyrus, 13.8 in the temporal gyrus, 13.58 in the straight gyrus,  
121 7.5 in the precentral gyrus and 6.24 in the angular gyrus, for a total of 50.34 LBs in  
122 neocortical brain regions.<sup>8</sup> According to estimates, the approximate number of neurons  
123 in the neocortex is 21 billion.<sup>9</sup> Assuming the total number of neurons in the neocortex  
124 and the observed number of LBs in neocortical gyri,  $2.397 \times 10^{-9}\%$  of neurons in the  
125 neocortex contain a LB in Parkinson's Disease (*i.e.* 1 in ~400 million neurons). More  
126 conservatively, using the total number of LBs observed by Mattila *et. al.*<sup>8</sup> in not just  
127 neocortical regions and presuming that all gyri mentioned contain 20% of the total  
128 number of neurons in the neocortex, this fraction still is exceedingly small at  
129  $79.33/4,200,000,000 = 1.888 \times 10^{-8}$  (*i.e.* 1 in ~50 million neurons). This evidence  
130 shows that Lewy Bodies are an exceedingly rare event at the neuronal cell population  
131 level. We urge caution in the interpretation of this value; however, it does serve to  
132 demonstrate the rarity of LB formation.  
133

134

### **Section S2. Brain region choice rationale after Braak**

135 The brain regions Frontal Cortex (FC), Parahippocampal Cortex (PC) and Caudate  
136 Nucleus (CAU) were chosen as representative brain regions for no Lewy pathology  
137 (LP), mild LP and moderate LP, respectively, according to Braak.<sup>5,6</sup> In the Braak  
138 staging used for neuropathological characterization of the samples, the Caudate  
139 Nucleus is moderately affected with substantial evidence of LP due to its direct  
140 proximity to the *Substantia Nigra*. The Parahippocampal Cortex first becomes affected  
141 in Braak stage 4, meaning LP deposition is currently ongoing in samples from patients  
142 classified as Braak 3/4. Neocortical lobes, such as the frontal, parietal and temporal  
143 cortices first show sparse LP in Braak stage 5–6, meaning very few to no LBs are  
144 expected in Braak 3/4.  
145

146

### **Section S3. Antibody requirements posed by ASA-PD**

147 The previously established ASA-PD protocol for single diffraction-limited  $\alpha$ Syn  
148 aggregate detection necessitates specific probe characteristics in order to enable the  
149 detection of these aggregates.<sup>2</sup> The detection of aggregates can only be possible if  
150 local intensity maxima arise as a consequence of probe (here antibody) binding to  
151 their targets. If an antibody binds  $\alpha$ Syn with a high specificity and affinity, it is likely to  
152 abundantly bind monomeric protein which is abundant in brain samples, thereby  
153 effectively increasing the overall background signal. A sufficiently low background  
154 signal is required in order to accurately detect dim local maxima produced by  
155 antibodies binding nanoscale assemblies with approximately  $>3$  antibody binding  
156 events per oligomer. If the background produced by an antibody due to its binding of  
157 monomeric protein is above the intensity of a nanoscale aggregate, the antibody is not  
158 suitable for the ASA-PD protocol, despite its high sensitivity and affinity. Equally,  
159 conditions for antibodies are set by the RASP pipeline which is used to detect and  
160 quantify technical true positives from the raw microscopy data.<sup>1</sup> Accurate quantification  
161 of diffraction-limited local maxima which are oligomers of  $\alpha$ Syn necessitates sufficient  
162 spatial separation between maxima, or sparsity. Selection of an antibody targeting  
163 pS129  $\alpha$ Syn allowed for sub-setting of all possible  $\alpha$ Syn epitopes in the sample which  
164

165 increased the visual sparsity of signal compared to an antibody targeting a generic  
166 epitope on the protein. This is shown in **Figure S2** which highlights that of the  
167 antibodies tested, only anti-pS129 gives the sufficient sparsity necessary for our  
168 imaging protocol. However, this evidence does not preclude the use of new probes  
169 against  $\alpha$ Syn with the abovementioned protocols, providing they meet the necessary  
170 conditions.

171

#### **Section S4. Summary bar graph computation**

172 The summary bar graphs in **Figure 3 A + Figure 3 B** show the mean ratio of the HC  
173 histogram over the PD histogram computed bin-by-bin with error bars are the standard  
174 deviation across bins. For Figure 3 B, this is achieved by computing the histogram of  
175 PD/HC ratios of ASCs (%).

176

#### **Section S5. Scanning threshold application**

177 **Figure 2 C.** shows the quantification of aggregation susceptible cells (ASCs) through  
178 a scanning threshold on the distribution of intracellular  $\alpha$ Syn concentrations of neurons  
179 for each brain region in PD patients and HCs. Essentially, we aim to test whether there  
180 are proportionately more cells containing a higher aggregate concentration in PD than  
181 in HCs. Classically, the  $1.5 \times$  interquartile range (IQR) rule has been used to define an  
182 outlier, *i.e.* an unexpectedly high value, given an approximately normal distribution.<sup>10</sup>  
183 However,  $1.5 \times$  IQR presumes an approximately normal distribution and is less robust  
184 to skewed distributions and lower n-numbers. Therefore, we chose to apply a scanning  
185 threshold to the distribution of aggregate concentration per cell values in each brain  
186 region. For each brain region, the scanning threshold starts at the mean value of a  
187 joint PD + HC distribution of aggregates per neuron. Then, the threshold is increased  
188 in increments of  $\mu + (0.01 \times \text{IQR})$ . At each increment of threshold, the proportion of  
189 ASCs is quantified for both the PD and HC distributions separately by dividing the  
190 number of cells above the current threshold value of aggregate concentration over all  
191 cells observed in the patient group's brain region. This approach ultimately yields a  
192 more robust observation of the overall degree of separation between the PD and HC  
193 distributions and the relative abundance of high-concentration ASCs as a function of  
194 the threshold that can be seen in **Figure 3 B.** Importantly, this data shows that the  
195 determination and setting of a threshold to identify an ASC interacts with the relative  
196 difference in prevalence of ASCs when comparing the PD and HC groups. As  
197 thresholds are set at increasingly extreme values of the distribution ( $\mu + \sim 2.0 \times \text{IQR}$ ),  
198 very few cells have as extreme values in both groups, and the data becomes less  
199 reliable and more error prone as sampling is limited. Reliably,  $\mu + 1.5 \times \text{IQR}$  shows  
200 the most robust difference observed between ASC abundance in PD and HC (**Figure**  
201 **3 B.**).

202

#### **Section S6. Kernel density estimates**

203 In Fig. 3B we utilised a kernel density estimation (KDE) plot, specifically the kdeplot  
204 function from seaborn.<sup>11</sup> This was utilised as, with the relatively low numbers of data  
205 points for a 2D histogram, outliers visually skew the distribution observed whilst  
206 contributing very little to the actual form of the distribution. A KDE plot is far less  
207 sensitive to these issues, and highlights the underlying shape of the distribution  
208 observed. KDEs are in essence the basis of violin plots, and due to their nonparametric  
209 nature and reliability in presenting the underlying forms of distributions,<sup>12</sup> we chose to  
210 use them here.

211

#### **Section S7. Data processing code availability**

216 Code used in this paper is available at (<https://doi.org/10.5281/zenodo.16411305>).  
217 The code package, "pyRASP\_copy\_for\_paper.zip", contains the python code used in  
218 the paper for image analysis and for postprocessing of the image analysis. This  
219 postprocessing involves determining if a single oligomer is inside or outside of a cell  
220 and determining, for single cells,  $[\alpha\text{Syn Aggregate}]_{\text{cell}}$ . A notebook in this zip folder  
221 takes the user through the process of loading in raw data and determining  $[\alpha\text{Syn}$   
222 Aggregate] $_{\text{cell}}$ . A comprehensive database file of all analysed data is also provided.

| Case ID | Sex | Age of Onset | Age at Death | Disease Duration | PMI | NPD     | αSyn Braak | Tau Braak | AB Thal |
|---------|-----|--------------|--------------|------------------|-----|---------|------------|-----------|---------|
| PD1     | F   | 65           | 75           | 10               | 14  | LBDBS   | 4          | 2         | NA      |
| PD2     | F   | 77           | 86           | 9                | 22  | LBDBS   | 4          | 2         | NA      |
| PD3     | M   | 66           | 72           | 6                | 9   | LBDBS   | 4          | 2         | NA      |
| PD4     | F   | 71           | 82           | 11               | 16  | LBDBS   | 3          | NA        | NA      |
| PD5     | M   | 70           | 85           | 15               | 16  | LBDBS   | 4          | 2         | NA      |
| PD6     | M   | 62           | 78           | 16               | 11  | LBDL    | 4          | NA        | NA      |
| PD7     | M   | NA           | 86           | 19               | 16  | LBDBS   | 3          | 1         | NA      |
| PD8     | M   | NA           | 81           | 17               | 22  | LBDL    | 4          | 2         | NA      |
| PD9     | F   | NA           | 76           | 25               | 8   | LBDL    | 4          | 1         | 1       |
| PD10    | M   | NA           | 77           | 1                | 24  | LBDL    | 4          | 2         | 3       |
| PD11    | M   | NA           | 69           | 16               | 13  | LBDBS   | 3          | 2         | 2       |
| PD12    | M   | NA           | 73           | 7                | 24  | LBDBS   | 3          | 1         | 3       |
| PD13    | M   | NA           | 78           | 21               | 19  | LBDL    | 4          | 1         | 1       |
| PD14    | M   | NA           | 91           | 17               | 6   | LBDBS   | 4          | 2         | NA      |
| HC1     | M   | NA           | 71           | NA               | 29  | Control | NA         | NA        | NA      |
| HC2     | M   | NA           | 88           | NA               | 8   | Control | NA         | NA        | NA      |
| HC3     | F   | NA           | 92           | NA               | 24  | Control | NA         | NA        | NA      |
| HC4     | F   | NA           | 87           | NA               | 12  | Control | NA         | NA        | NA      |
| HC5     | M   | NA           | 90           | NA               | 12  | Control | NA         | NA        | NA      |
| HC6     | M   | NA           | 87           | NA               | 31  | Control | NA         | NA        | NA      |
| HC7     | M   | NA           | 75           | NA               | 24  | Control | NA         | NA        | NA      |
| HC8     | F   | NA           | 84           | NA               | 22  | Control | NA         | NA        | NA      |
| HC9     | M   | NA           | 75           | NA               | 17  | Control | NA         | NA        | NA      |
| HC10    | F   | NA           | 89           | NA               | 13  | Control | NA         | NA        | NA      |
| HC11    | M   | NA           | 82           | NA               | 48  | Control | NA         | NA        | NA      |
| HC12    | M   | NA           | 75           | NA               | 12  | Control | NA         | NA        | NA      |
| HC13    | F   | NA           | 89           | NA               | 20  | Control | NA         | NA        | NA      |

223 **Table S1.** Case demographics of study cases. Parkinson's disease (PD) cases and  
224 neurologically normal control (HC) cases. PMI – Post-mortem interval; NPD –  
225 Neuropathological diagnosis; LBDBS – Lewy Body Disease Brainstem predominant; LBDL –  
226 Lewy Body Disease Limbic predominant; NA – Data not available.  
227  
228

229 **Supplementary References**

230 1. Fu, B. *et al.* RASP: Optimal Single Puncta Detection in Complex Cellular  
231 Backgrounds. *J. Phys. Chem. B* **128**, 3585–3597 (2024).

232 2. Andrews, R. *et al.* Large-scale visualisation of  $\alpha$ -synuclein oligomers in Parkinson's  
233 disease brain tissue. *bioRxiv : the preprint server for biology* 2024.02. 17.580698 (2024).

234 3. Marian, P. & Marian, T. A. Hellinger distance as a measure of Gaussian discord.  
235 *Journal of Physics A: Mathematical and Theoretical* vol. 48 115301 (2015).

236 4. Kitsos, C. & Toulias, T. Hellinger distance between generalized normal distributions.  
237 *Br. J. Math. Comput. Sci* vol. 21 1–16 (2017).

238 5. Dickson, D. W., Uchikado, H., Fujishiro, H. & Tsuboi, Y. Evidence in favor of Braak  
239 staging of Parkinson's disease. *Movement Disorders* vol. 25 S78–S82 (2010).

240 6. Braak, H. *et al.* Staging of brain pathology related to sporadic Parkinson's disease.  
241 *Neurobiology of aging* vol. 24 197–211 (2003).

242 7. Greffard, S. *et al.* A stable proportion of Lewy body bearing neurons in the substantia  
243 nigra suggests a model in which the Lewy body causes neuronal death. *Neurobiology of  
244 aging* vol. 31 99–103 (2010).

245 8. Mattila, P. *et al.* Alpha-synuclein-immunoreactive cortical Lewy bodies are associated  
246 with cognitive impairment in Parkinson's disease. *Acta neuropathologica* vol. 100 285–  
247 290 (2000).

248 9. Williams, R. W. & Herrup, K. The control of neuron number. *Annual review of  
249 neuroscience* vol. 11 423–453 (1988).

250 10. Yang, J., Rahardja, S. & Fränti, P. Outlier detection: How to threshold outlier scores?  
251 *Proceedings of the international conference on artificial intelligence, information  
252 processing and cloud computing* 1–6.

253 11. Waskom, M. L. Seaborn: statistical data visualization. *Journal of open source  
254 software* vol. 6 3021 (2021).

255 12. Chen, Y.-C. A tutorial on kernel density estimation and recent advances. *Biostat. &  
256 Epidemiol.* **1**, 161–187 (2017).